1 Filling the Holes in Part D: SPAPs to the Rescue? Marc Steinberg, Families USA Health Action 2005 * January 27, 2005 202-628-3030.

Slides:

Advertisements

Similar presentations

H.B. Fuller Company 2010 Open Enrollment: Helping you Buy Well, Use Well, Be Well October, 2009.

Advertisements

Massachusetts Health Care Reform June 6, The healthcare status quo is unsustainable Double-digit, annual increases in insurance premiums Half.

1 Medicare Part D: Cost Management Issues Jack Hoadley Research Professor Georgetown University Health Policy Institute Families USA Health Action 2005.

Part Ds Low-Income Benefits: Theory and Reality Marc Steinberg, Families USA Health Action 2006 January 26, 2006 ** Washington, DC

1 Private Insurance: What State Advocates Need to Know Cheryl Fish-Parcham Families USA January 25, 2007.

TRENDS IN MEDICAID WAIVERS Judith Solomon Center on Budget and Policy Priorities Families USA Conference January 26, 2006.

Part D Price Negotiation: Why we need it Marc Steinberg, Families USA Health Action 2007 * Washington, DC January 25, 2007

K A I S E R C O M M I S S I O N O N Medicaid and the Uninsured Figure 0 The Transition of Dual Eligibles to Medicare Drug Coverage: Implications for Beneficiaries.

The Perils and Promise of Medicare Part D Marc Steinberg, Families USA Making Public Programs Work for Communities of Color January 25, 2006 ** Washington,

FY 06 Medicaid Budget Cuts: And the Fight Goes On… Health Action 2006 Saturday January 28, 2006 Rachel Klein Families USA

Universal Coverage and Access: Critical to Achieving Health Equity Getting to Universal Coverage and Access A Congressional Briefing Ron Pollack Families.

Medicare’s Role Medicare covers 47 million Medicare beneficiaries

This presentation contains confidential and proprietary information of Caremark and cannot be reproduced, distributed, or printed without written permission.

Medicare and Prescription Drugs: Issues for Employers and Consumers Robert D. Reischauer The Urban Institute National Health Policy Conference January.

The Impact of Drug Benefit Caps Geoffrey Joyce, PhD.

Medicare and New and Existing Opportunities for Financial Assistance National Association of Health Underwriters June 2009.

State Health Insurance Assistance Program

Illinois Cares Rx What Happens Behind the Scenes.

Federal Medicare Prescription Drug Coverage Sam Shore Center for Policy and Innovation DSHS.

Need vs. Want o Filet mignon or hamburger o Vioxx or aspirin Employee noise and understanding Provider resistance Funds for accounts 2.

Medicare Prescription Drug Discount Card Ranjani Varadarajan PYPC 7810.

A Presentation of the Colorado Health Institute 1576 Sherman Street, Suite 300 Denver, Colorado Hot Issues in.

1 ISD 15 St Francis 2012 Retiree/COBRA Open Enrollment Meeting April 2012.

Education, Sales and Enrollment Presentation 2008 PowerPoint Presentation M0018_TO_PPT_0907 CMS (Pending CMS Approval) H5421 Today’s Options.

Commonwealth Connector Minimum Pharmacy Standards October 11, 2007.

Medicare Part D John A. Geib 10/3/05. Medicare Modernization Act (MMA) 2003 and How the MMA impacts California’s Medi-Cal Program Largest change in healthcare.

Insurance Options under the Affordable Care Act Brendan Riley NC Community Health Center Association January 23, 2014.

Adam J. Falk, Esq. FELDESMAN TUCKER LEIFER FIDELL LLP Legal issues for Medicaid Plans Under Part D in Serving Dual Eligibles MEDICAID HEALTH PLANS OF AMERICA.

Challenges of Serving Low-income Medicare Beneficiaries: Impact of Cost Sharing Cindy Parks Thomas Brandeis University Schneider Institute for Health Policy.

Coordination of Benefits and TrOOP Tracey McCutcheon Center for Beneficiary Choices CMS.

The Evolving Role of States in the Medicare Drug Benefit Thomas M. Snedden, Director Pennsylvania PACE Program The Third National Medicare Congress October.

Pharmaceutical Assistance Contract for the Elderly (PACE) Program began July 1, 1984 PACE Needs Enhancement Tier (PACENET) Program began January 1, 1997.

Medicare Part D Nari Wang Health Law Unit 199 Water Street New York, NY Center for Independence of the Disabled, NY February 23, 2010.

Medicare Part D and HIV/AIDS: What a Clinician May Want to Know Laura Cheever, M.D., ScM Deputy Director, Chief Medical Officer HIV/AIDS Bureau Health.

THE AIDS INSTITUTE The AIDS Institute HEALTH REFORM AND ADAP Emily McCloskey, Public Policy Associate Carl Schmid, Deputy Executive Director AIDS Drug.

MEDICARE: PAST, PRESENT AND FUTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.

MEDICARE: PAST, PRESENT AND F UTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.

Deciphering Medicare Part D Susan Miller, Patient Education Douglas A. Magenheim, MD, MBA, FACP.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health? Get Educated, Get Enrolled An.

Rutgers Center for State Health Policy June 28, 2005 Presentation to the Academy Health Kimberley Fox, Senior Policy Analyst Rutgers Center for State Health.

1 State Perspectives on Medicare Part D: Lessons from Pharmacy Plus Programs Cindy Parks Thomas Donald Shepard Christine E. Bishop Daniel M. Gilden Brandeis.

© 2005 National Mental Health Association The Medicare Drug Benefit: What Is It and What Does it Mean for Mental Health?

Medicare in Minnesota 2012 Your Medicare: Making the Best Possible Decisions October 2011 Presented by Stephanie Minor Senior LinkAge Line® Program Consultant.

Medicare Prescription Drug Benefit: Part D Health & Disability Advocates Stephanie Altman, J.D Ext

1 Medicare Prescription Drug Improvement and Modernization Act & Beneficiaries With Mental Illnesses Presentation to NAMI Convention June 19, 2005 Andrew.

Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Roy Trudel, CMSO National Eligibility Workers Association 07/12/05.

1 Maryland SPAP Premium Subsidies to MedicareRx Plans National Association of Comprehensive Health Insurance Plans October 16, 2008 Richard Popper Executive.

MEDICARE PART D Are We Ready? Are We Ready?. Medicare Part D Overview Medicare Part A and B covers individuals Age 65 and older Age 65 and older Those.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy.

January National Medicare & You Training Program Amy Larrick, CMS NAACP April 27, 2006.

Medicare, Medicaid, and Health Care Reform Todd Gilmer, PhD Professor of Health Policy and Economics Department of Family and Preventive Medicine 1.

Medicare and Patient Assistance Sean M. Dougherty Senior Director Medicare Strategy & Patient Assistance Programs Government, Public Policy And Managed.

The New Medicare Prescription Drug Benefit: An Overview Prepared by: Michelle Kitchman, M.H.S. Kaiser Family Foundation For the: California Senate Health.

11/8/051 Medicare Prescription Drug Benefits Employee Workshop November 2005.

Avalere Health LLC | The intersection of business strategy and public policy The Potential Impact of the New Prescription Drug Benefit on Medicare Beneficiaries.

Stretching Program Dollars: Creative Solutions in Cost Containment Presentation to aaa+ ADAP Crisis Summit July 6, 2010.

Ian D. Spatz Merck & Co., Inc. January 14, 2004 Ian D. Spatz Merck & Co., Inc. January 14, 2004 Overview of the New Medicare Prescription Drug Law.

"Helping Seniors Make Smart Decisions about their Drug Coverage Options" Hal Prink, FHFMA, Medicare Patient Advocate, Senior’s Voice for Healthcare Rights.

Avalere Health LLC | The intersection of business strategy and public policy The Medicare Modernization Act: The Impact on States and Low-Income Beneficiaries.

1 Cost Sharing for Low-Income Beneficiaries and Supplementing Part D Examples from Pharmacy Plus Medicaid Demonstration Programs Summit for State Health.

Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Deirdre Duzor Director, Pharmacy Division Centers for Medicare & Medicaid Services.

1 State Options for Supplementing Medicare Part D Drug Coverage Invitational Summit on Medicare Part D Implementation Issues Jack Hoadley Georgetown University.

National Conference of State Legislatures National Medicaid Congress June 5, 2006 State Pharmaceutical Assistance Programs, Medicaid & Part D: 2006 State.

State Responses to Medicare Part D Presented by: Kimberley Fox, Senior Policy Analyst, Institute for Health Policy Academy Health Annual Research Meeting.

Overview of the Medicare Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family.

2018 Medicare Prescription Drug Benefit

Director, Pennsylvania PACE Program National Medicare Congress

Medicare Rx Drug Benefit

Presented by Tricia Neuman, Sc.D.

Medicare Part D Implementation Issues: Key Decisions for States

Presentation transcript:

1 Filling the Holes in Part D: SPAPs to the Rescue? Marc Steinberg, Families USA Health Action 2005 * January 27,

2 State Pharmaceutical Assistance Programs (SPAPs) 38 states: 22 benefit programs, 16 discount programs 1.3 million enrollees in benefit programs: 54% in 3 states: NJ, NY, PA Most cover seniors only; a few cover seniors & disabled or more Some benefit caps Few have asset test for eligibility

3 SPAP Income Eligibility, 2002 source: Trail, Fox, Cantor, Silberberg, & Crystal, 2004

4 Why SPAPs Matter for Medicare Part D SPAP beneficiaries are major targets of Part D Significant savings for SPAPs likely Can identify low-income beneficiaries, but asset test is a problem SPAP help can fill the donut hole and other gaps in coverage Counts towards a beneficiarys TROOP (true out- of-pocket cost)

5 Gaps SPAPs could fill Premiums Deductible Co-insurance Co-payments Non-formulary drugs Non-network purchases

6 Choices for States Wrap around Part D with existing or new SPAP? Could be major help for beneficiaries Costs are uncertain (e.g. non-formulary drugs) Covering additional drugs is administratively complex

7 Other Choices for States Continue existing SPAP with minimal changes As secondary payer? Similar to a wraparound As alternative plan? - not likely a long-term solution Abolish SPAP Politically safe in some states Lost opportunity

8 Building a Wraparound SPAP: Coordination Problems Filling gaps means coordination of benefits; harder with multiple plans States cannot: discriminate among plans Auto-enroll SPAP members in preferred plan Steer SPAP members to preferred plan States can: Act as an authorized representative (per state law) and auto-enroll at random Compare plans for members

9 Building a Wraparound SPAP: Additional Problems Who will be covered? Different federal subsidy levels mean different benefits Appeals: SPAP could have interest in appealing denial of coverage SPAP can appeal if it is an authorized representative per state law Multi-state regions add complexity

10 Questions to Ask If state has an SPAP: Will program continue in 2006? What savings are projected Is wraparound an option? If so, what type? Who and what are covered? What role in low-income subsidy determination?

11 Questions to Ask If state does not have an SPAP: Can state create one in coming years Who and what could be covered?

12 Summary SPAPs have potential to ease burdens on low-income Medicare beneficiaries Can make Part D a more complete benefit Substantial administrative complexity is likely Few states have made decisions yet

13 Appendix: Benefit Levels

14 Low-Income Subsidy, Tier 1 Income: under 135% FPL Assets: below $6,000/individual, $9,000/couple Asset limits increase with consumer price index Premium: full subsidy (average for region) Copays: $2 generics/ $5 non-generics No copayments when total costs exceed $5,100 Copays and catastrophic limit increase with Medicare drug inflation

15 Low-Income Subsidy, Tier 2 Income: 135%-150% FPL or Under 135% and over assets Assets: Under $10,000/individual or $20,000/couple Assets increase w/ CPI Premium: sliding scale of $0-$35/month (increases annually) $50 annual deductible 15% co-insurance up to $5,100 drug costs $2/$5 copays after drug costs reach $5,100/year Copays and catastrophic limit increase with Medicare drug inflation

16 Low-Income Subsidy for Full Dual Eligibles (Part 1) Institutionalized Premium: full subsidy (average for region) No copayments Income up to 100% FPL Premium: full subsidy (average for region) Copays: $1/generic & $3/non-generic No Copays after total drug costs reach $5,100/year Copays indexed to consumer price index Catastrophic limit increases with Medicare drug inflation

17 Low Income Subsidy for Full Dual Eligibles (Part 2) Income over 100% FPL Premium: full subsidy (average for region) Copays: $2/generic & $3/non-generic No Copays after total drug costs reach $5,100/year Co-pays indexed to Medicare drug spending Catastrophic limit increases with Medicare drug inflation

18 Medicare Part D Basic Benefit (all dollar amounts are indexed to Medicare drug costs) CoverageDrug Costs Part D Pays You Pay Tot. Costs (TROOP) Deductible$0-2500%100%$250 Initial Benefit $251- $ %25%$750 Donut Hole$2251- $5100 0%100%$3600 CatastrophicOver $ %5%$3600 plus 5% of remainder